consulting

View All

COMMON COLD
Potential cure for Common cold

A group of Researchers at Imperial College London created a molecule that can successfully block multiple strains of the common cold by targeting a protein required for the survival of the virus. The newly created molecule (IMP-1088) resides inside a protein in cells called N-myristoyltransferase (NMT). After invadi...

Find More

Delveinsight
Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs

Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs After a rough journey in 2017, the road seems clear for French CAR-T specialist Cellectis, which has recently closed a USD 164 million U.S. public offering. Out of total funding amount around USD 100 million will be used to build commerc...

Find More

Delveinsight
Hepatic Encephalopathy- Lack of active pipeline products

Hepatic encephalopathy (HE) can be described as deterioration of brain function occurring due to accumulation of toxic substances in the blood which ultimately reach the brain. People with long-standing or chronic liver disorder are at high risk. The disease may also be triggered by bleeding in the digestive tract,...

Find More

CELIAC DISEASE
Celiac Disease – Intestinal damage of Gluten

Celiac Disease (Gluten-Sensitive Enteropathy) is a chronic, autoimmune, inflammatory disease of the small intestine characterized by damage to the lining of the small intestine and typically leads to dyspepsia, malabsorption and a variety of other symptoms. Individuals with Celiac Disease carry DQ2 or DQ8 MHC class ...

Find More

Delveinsight
Business Cocktail

Pharma startup Bonti has recently grabbed a funding of USD 15 million Managed by Ex-Allergan executives biotech startup Bonti has recently bagged a funding of USD 15.5 million in series C, The Company is focused on developing a new botulinum neurotoxin for both therapeutic and cosmetic uses. Funding will help in the...

Find More